Dr. Mehran Khorsandi, Chairman and Founder of Advanced Bifurcation Systems stated, “ABS is very excited about commencing clinical trials within the New Brunswick health care system. The high quality of the interventional cardiologists, combined with the excellence of the New Brunswick health care system and the institutions that support it, will provide a great resource for us when we initiate our clinical trials.”
Mr. Charles Laverty, Chief Executive Officer of Advanced Bifurcation Systems commented, “We believe the quality of the data from the clinical trials will mirror the strong reputation of outcomes within the New Brunswick health care system and look forward to working with this outstanding team.”
“The NBHRF facilitates and supports the Health Research Enterprise in New Brunswick. We are pleased to witness the interest and commitment of ABS in medical device innovation as well as recognizing the expertise of the Specialists and health professionals at the NBHC and the HHN Research Services. The conduct of clinical research and clinical trials in New Brunswick is a great testament to our efforts at building out our health research capacity,” says Dr. Bruno Battistini, President, CEO and Scientific Director of the New Brunswick Health Research Foundation.
“ONB is always looking at how to leverage New Brunswick’s strengths to bring new opportunities here that will generate economic growth and skilled jobs for New Brunswickers,” said ONB CEO Stephen Lund. “This province has world-class assets in the health-research sector, and it is drawing interest from innovative companies like Advanced Bifurcation Systems (ABS) Inc. We are excited to see what ABS can achieve in New Brunswick.”
Upon successful completion of the human clinical trials, ABS intends to establish a manufacturing facility in New Brunswick, to serve ABS’s customers globally. ABS has incorporated a Canadian subsidiary, Advanced Bifurcation Systems Canada, Inc. to support this effort.
About Advanced Bifurcation Systems
Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com.
About OPPORTUNITIES NB
Opportunities NB is a Crown corporation that seeks to attract and support opportunities to grow the economy and create jobs. It provides support services for businesses across the province.
About the New Brunswick Health Research Foundation
The New Brunswick Health Research Foundation (NBHRF) was created in July 2008 with a mandate to co-ordinate, support and promote health research in New Brunswick. Our vision is a healthy and prosperous New Brunswick through excellence in health research and innovation. Our mission is to provide leadership and support to build health research capacity, improve the health of New Brunswickers and advance the knowledge economy.
The NBHRF is an independent organization governed by a board of directors comprised of key stakeholders from the health research community in New Brunswick. Provincial funding is provided by Business New Brunswick.
Contact:
Advanced Bifurcation Systems
Charles Laverty
Chief Executive Officer
charles_laverty@advancedbifurcation.com
(949)432-4824
